Zurich Insurance Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Zurich Insurance Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-40,731	Closed	-$3.84M	–	458
2018 Q2	$3.84M	Buy	+40,731	New	+$3.57M	0.09%	279
2017 Q1	–	Sell	-21,878	Closed	-$1.81M	–	510
2016 Q4	$1.81M	Buy	+21,878	New	+$1.88M	0.06%	340

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Zurich Insurance Group's BMRN Position: Q3 2018 in Review

Zurich Insurance Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 40,731 shares — an estimated $3.84M sold.

Zurich Insurance Group first reported a position in BMRN in Q4 2016 and held it in 2 quarters. The position peaked at $3.84M in Q2 2018. 460 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

Zurich Insurance Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Zurich Insurance Group sold 40,731 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $3.84M.
Zurich Insurance Group first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 2 quarters.
Zurich Insurance Group's BioMarin Pharmaceuticals position peaked at $3.84M in Q2 2018.
460 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Zurich Insurance Group's 13F filing for Q3 2018, filed 14 Nov 2018.